id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2010-P-0642-0003,FDA,FDA-2010-P-0642,"Appendix 1 - ""Modulating Effects of Glatiramer Acetate on Some Cellular and Humoral Immune Responses""  [Teva Pharmaceutical Industries Ltd., Teva Neuroscience, Inc.  Citizen Petition]",Supporting & Related Material,CP-Citizen Petition (Supporting & Related Materials),2010-12-17T05:00:00Z,2010,12,,,2010-12-17T16:40:55Z,,0,0,0900006480bb85b1
FDA-2010-P-0642-0001,FDA,FDA-2010-P-0642,"Teva Pharmaceutical Industries Ltd., Teva Neuroscience, Inc. - Citizen Petition",Other,CP-Citizen Petition,2010-12-17T05:00:00Z,2010,12,2010-12-17T05:00:00Z,,2011-06-16T12:40:15Z,,0,0,0900006480bb890d
FDA-2010-P-0642-0002,FDA,FDA-2010-P-0642,"Acknowledgement Letter to Teva Pharmaceutical Industries Ltd., Teva Neuroscience, Inc.",Other,ACK-Acknowledgement Letter,2010-12-17T05:00:00Z,2010,12,2010-12-17T05:00:00Z,,2013-07-27T23:39:53Z,,0,0,0900006480bb890e
FDA-2010-P-0642-0004,FDA,FDA-2010-P-0642,"Appendix 2 - ""Safety and Immunogenicity Assessment of Glatiramer Acetate Follow-on Products (Glatiramoids)""  [Teva Pharmaceutical Industries Ltd., Teva Neuroscience, Inc.  Citizen Petition]",Supporting & Related Material,CP-Citizen Petition (Supporting & Related Materials),2010-12-17T05:00:00Z,2010,12,,,2010-12-17T16:40:57Z,,0,0,0900006480bb8d8c